PODD
Insulet Corporation (PODD) Sec Form 8K
Insulet Corporation (NASDAQ: PODD) Sec Form 8K
Insulet Corporation (PODD) Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S.
Insulet Corporation (NASDAQ: PODD) FY 2026 Other Release
Insulet Corporation (PODD) Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) FY 2026 Other Release
Insulet Corporation (PODD) Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Insulet Corporation (NASDAQ: PODD) FY 2026 Other Release
Insulet Corporation (PODD) Sec Form 8K
Insulet Corporation (NASDAQ: PODD) Sec Form 8K
Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ: PODD) Q4 2025 Earnings Call dated Feb. 18, 2026 Corporate Participants: Clare Trachtman — Vice President of…
Insulet Corporation (PODD) Sec Form 10K
Insulet Corporation (NASDAQ: PODD) Sec Form 10K
Insulet Corporation (PODD) Sec Form 8K
Insulet Corporation (NASDAQ: PODD) Sec Form 8K
Insulet Corporation Reports 31% Annual Revenue Growth; Authorizes $350 Million Repurchase Increase
The global medical technology leader exceeded 2025 financial targets behind a 44% surge in international sales and the expansion of…
Insulet Corporation (PODD) Q4 2025 Earnings Results
Insulet Corporation (NASDAQ: PODD) Q4 2025 Earnings Release